Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
StockNews.AI · 2 hours
AI Summary
Travere Therapeutics reported five-year results from the DUPLEX trial's open-label extension, showing durable proteinuria reductions with FILSPARI in FSGS and rapid, sustained improvements when patients switched from irbesartan. In the double-blind phase, complete remission was 18.5% vs 7.5% and partial remission 69.0% vs 50.8%. Open-label results and upcoming ERA data reinforce FILSPARI's potential as foundational care, though hepatotoxicity REMS remains a safety headwind.
Sentiment Rationale
Durable efficacy signals and favorable remission rates raise confidence in FILSPARI's long-term potential, potentially improving multiple valuation metrics; however, REMS safety constraints create a balanced risk profile.
Trading Thesis
Bullish near-term; expect TVTX to rise on durable efficacy signals and ERA data catalysts over weeks to months.
Market-Moving
- Five-year durability of proteinuria reductions strengthens FILSPARI's long-term value proposition.
- Hepatotoxicity REMS and boxed warnings may cap upside despite efficacy gains.
- ERA 2026 gdIgA mechanism data could broaden the addressable kidney disease population.
- Strong double-blind remission signals (CR/PR) vs irbesartan set a high efficacy baseline.
Key Facts
- DUPLEX open-label extension shows durable proteinuria reductions for up to five years. Patients who stayed on FILSPARI maintained low proteinuria thresholds.
- DB period: complete remission 18.5% vs 7.5%; partial remission 69.0% vs 50.8%.
- Open-label extension: rapid, sustained reductions when switching from irbesartan to FILSPARI. CR 28.9%, PR 74.6% in switch group.
- OLE data indicate safety consistent with prior findings; REMS and hepatotoxicity risk remain management considerations.
- ERA 2026 Glasgow meeting will share preclinical gdIgA mechanism data supporting FILSPARI's potential mechanism.
Companies Mentioned
- Travere Therapeutics, Inc. (TVTX): Long-term DUPLEX data bolster FILSPARI's durability in FSGS; potential positive valuation implications.
Industry News
Industry News: This is a clinical trial data release with potential corporate and valuation impact for Travere.